Molecular Basis for the Treatment of Renal Cell Carcinoma

Overview

Journal Clin Transl Oncol

Specialty Oncology

Date 2010 Jan 19

PMID 20080466

Citations 7

Authors

Cristina Suarez

Rafael Morales

Eva Munoz

Jordi Rodon

Claudia M Valverde

Joan Carles

Affiliations

Soon will be listed here.

Abstract

Renal cell carcinoma (RCC) is a heterogeneous malignancy whose incidence rate has notably increased in recent years without any evident reason. Traditionally, RCC has been resistant to classic treatments (chemotherapy, radiotherapy and hormonal therapy), with only a small percentage of patients benefiting from cytokine therapy. Different hereditary syndromes have been associated with RCC, Von Hippel Lindau (VHL) being the most important syndrome. Understanding key molecular pathways implicated in the tumorigenesis of RCC has crystallised in the development of more effective therapies. Specifically, drugs targeting VEGF (bevacizumab, sunitinib, sorafenib, axitinib, pazopanib) and PI3K-mTOR (temsirolimus and everolimus) have become the cornerstone of renal cancer treatment.

Citing Articles

The Effects of Chinese Herbal Decoction Combined with Recombinant Human Interferon 2b on MRI Imaging, Tumor Markers, and Immune Function in Patients with Renal Cell Carcinoma.

Song S, Li W, Liang W, Tian X Evid Based Complement Alternat Med. 2021; 2021:8106974.

PMID: 34733345 PMC: 8560232. DOI: 10.1155/2021/8106974.

Identification of Four Pathological Stage-Relevant Genes in Association with Progression and Prognosis in Clear Cell Renal Cell Carcinoma by Integrated Bioinformatics Analysis.

Xu D, Xu Y, Lv Y, Wu F, Liu Y, Zhu M Biomed Res Int. 2020; 2020:2137319.

PMID: 32309427 PMC: 7142335. DOI: 10.1155/2020/2137319.

Improving patient selection for adjuvant therapy in high-risk renal cell carcinoma.

Buller D, Ristau B Ann Transl Med. 2019; 7(Suppl 3):S104.

PMID: 31576311 PMC: 6685884. DOI: 10.21037/atm.2019.04.75.

Expression and significance of histone H3K27 demethylases in renal cell carcinoma.

Shen Y, Guo X, Wang Y, Qiu W, Chang Y, Zhang A BMC Cancer. 2012; 12:470.

PMID: 23057811 PMC: 3520868. DOI: 10.1186/1471-2407-12-470.

Immunoexpression status and prognostic value of mTOR and hypoxia-induced pathway members in primary and metastatic clear cell renal cell carcinomas.

Schultz L, Chaux A, Albadine R, Hicks J, Kim J, De Marzo A Am J Surg Pathol. 2011; 35(10):1549-56.

PMID: 21881486 PMC: 3505672. DOI: 10.1097/PAS.0b013e31822895e5.

References

Takahashi A, Sasaki H, Kim S, Tobisu K, Kakizoe T, Tsukamoto T . Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res. 1994; 54(15):4233-7. View

Birt A, HOGG G, Dube W . Hereditary multiple fibrofolliculomas with trichodiscomas and acrochordons. Arch Dermatol. 1977; 113(12):1674-7. View

Vocke C, Yang Y, Pavlovich C, Schmidt L, Nickerson M, Torres-Cabala C . High frequency of somatic frameshift BHD gene mutations in Birt-Hogg-Dubé-associated renal tumors. J Natl Cancer Inst. 2005; 97(12):931-5. DOI: 10.1093/jnci/dji154. View

Rini B, Wilding G, Hudes G, Stadler W, Kim S, Tarazi J . Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol. 2009; 27(27):4462-8. DOI: 10.1200/JCO.2008.21.7034. View

Fingar D, Salama S, Tsou C, Harlow E, Blenis J . Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev. 2002; 16(12):1472-87. PMC: 186342. DOI: 10.1101/gad.995802. View

Linehan W, Walther M, Zbar B . The genetic basis of cancer of the kidney. J Urol. 2003; 170(6 Pt 1):2163-72. DOI: 10.1097/01.ju.0000096060.92397.ed. View

Gnarra J, Zhou S, Merrill M, Wagner J, Krumm A, Papavassiliou E . Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc Natl Acad Sci U S A. 1996; 93(20):10589-94. PMC: 38197. DOI: 10.1073/pnas.93.20.10589. View

Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio P . Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell. 2003; 3(4):347-61. DOI: 10.1016/s1535-6108(03)00085-0. View

Maher E . Von Hippel-Lindau disease. Curr Mol Med. 2004; 4(8):833-42. DOI: 10.2174/1566524043359827. View

10.

Escudier B, Eisen T, Stadler W, Szczylik C, Oudard S, Siebels M . Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007; 356(2):125-34. DOI: 10.1056/NEJMoa060655. View

11.

Nicol D, Hii S, Walsh M, Teh B, Thompson L, Kennett C . Vascular endothelial growth factor expression is increased in renal cell carcinoma. J Urol. 1997; 157(4):1482-6. View

12.

Brauch H, Weirich G, Brieger J, Glavac D, Rodl H, Eichinger M . VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation. Cancer Res. 2000; 60(7):1942-8. View

13.

Nickerson M, Warren M, Toro J, Matrosova V, Glenn G, Turner M . Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dubé syndrome. Cancer Cell. 2002; 2(2):157-64. DOI: 10.1016/s1535-6108(02)00104-6. View

14.

Toro J, Nickerson M, Wei M, Warren M, Glenn G, Turner M . Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. Am J Hum Genet. 2003; 73(1):95-106. PMC: 1180594. DOI: 10.1086/376435. View

15.

Selak M, Armour S, MacKenzie E, Boulahbel H, Watson D, Mansfield K . Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell. 2005; 7(1):77-85. DOI: 10.1016/j.ccr.2004.11.022. View

16.

Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C . Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007; 370(9605):2103-11. DOI: 10.1016/S0140-6736(07)61904-7. View

17.

Bukowski R, Kabbinavar F, Figlin R, Flaherty K, Srinivas S, Vaishampayan U . Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol. 2007; 25(29):4536-41. DOI: 10.1200/JCO.2007.11.5154. View

18.

Wang G, Semenza G . General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci U S A. 1993; 90(9):4304-8. PMC: 46495. DOI: 10.1073/pnas.90.9.4304. View

19.

Sonpavde G, Hutson T . Pazopanib: a novel multitargeted tyrosine kinase inhibitor. Curr Oncol Rep. 2007; 9(2):115-9. DOI: 10.1007/s11912-007-0007-2. View

20.

Lonser R, Glenn G, Walther M, Chew E, Libutti S, Linehan W . von Hippel-Lindau disease. Lancet. 2003; 361(9374):2059-67. DOI: 10.1016/S0140-6736(03)13643-4. View